Cetuximab for treating non-small cell lung cancer.
Epidermal Growth Factor Receptor (EGFR)-dependent signaling plays a crucial role in epithelial cancer biology, and dictated the development of several targeting agents. The mouse-human chimeric antibody Cetuximab was among the first to be developed. After about two decades of clinical research it has gained a significant place in the management of advanced colorectal and head and neck cancers, whereas its development in non small cell lung cancer (NSCLC) has not led to a place in routine clinical practice, because of marginal clinical benefit despite statistically significant Phase III trials. Recent data from ongoing trials suggest that more careful selection based on molecular markers may identify good responders. Areas covered: In this article, the authors review the literature concerning basic science studies identifying EGFR as a therapeutic target, pharmacological development of Cetuximab, its pharmacodynamics and pharmacokinetics, and clinical trials on Cetuximab in NSCLC, focusing on recent findings on putative predictive biomarkers. Expert opinion: Cetuximab currently has no role in NSCLC treatment outside of research settings. We argue that failure to identify a predictive biomarker early on has hampered its chances to enter routine practice. Although recent research suggests benefit in highly selected patient subsets, its potential impact is severely dampened by lack of regulatory body approval and the emergence of competitors for the same niches.
['Mazzarella|Luca|L|', 'Guida|Alessandro|A|', 'Curigliano|Giuseppe|G|']
D000074322:Antineoplastic Agents, Immunological D002289:Carcinoma, Non-Small-Cell Lung D000068818:Cetuximab D002986:Clinical Trials as Topic D003131:Combined Modality Therapy D066246:ErbB Receptors D005076:Exanthema D006207:Half-Life D006801:Humans D008175:Lung Neoplasms
Cetuximab non small cell lung cancer Predictive biomarkers combination trials